文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护病房念珠菌血症患者继发性定位病灶的筛查、患病率及危险因素:法国CandidICU多中心研究

Screening, prevalence, and risk factors for secondary localization during candidemia in intensive care unit patients: the French CandidICU multicenter study.
PubMed 文献 · Crit Care · 2025-07-05
一句话结论在16个法国ICU的念珠菌血症患者中,76.4%接受了继发性定位病灶筛查,21.8%诊断出至少一个继发性定位病灶;SAPSII评分和血培养阳性持续时间是独立危险因素,年龄和光滑念珠菌感染为保护因素。

CandidICU研究为回顾性多中心队列,纳入2015年1月至2023年1月法国16个ICU收治的492例成人念珠菌血症患者,其中376例(76.4%)接受了继发性定位病灶筛查,82例(21.8%)诊断出至少一个继发性定位病灶。竞争风险分析显示SAPSII评分(sdHR 1.01,95%CI 1.00-1.02;p=0.031)和血培养阳性持续时间(sdHR 1.05,95%CI 1.02-1.08;p=0.003)为继发性定位病灶的独立危险因素,年龄(sdHR 0.98,95%CI 0.97-1.00;p=0.016)和光滑念珠菌感染(sdHR 0.38,95%CI 0.15-0.99;p=0.048)为保护因素。继发性定位病灶患者接受抗真菌治疗时间更长(18[11-30]天 vs 14[6-18]天;p<0.001),抗真菌药物升级比例更高(27.8% vs 12.3%;p=0.002)。

要点

  • 在16个法国ICU的492例念珠菌血症患者中,376例(76.4%)接受了继发性定位病灶筛查,82例(21.8%)诊断出至少一个继发性定位病灶。
  • SAPSII评分(sdHR 1.01,95%CI 1.00-1.02;p=0.031)和血培养阳性持续时间(sdHR 1.05,95%CI 1.02-1.08;p=0.003)是继发性定位病灶的独立危险因素。
  • 年龄(sdHR 0.98,95%CI 0.97-1.00;p=0.016)和光滑念珠菌感染(sdHR 0.38,95%CI 0.15-0.99;p=0.048)为继发性定位病灶的保护因素。
  • 继发性定位病灶患者抗真菌治疗时间更长(18[11-30]天 vs 14[6-18]天;p<0.001),抗真菌药物升级比例更高(27.8% vs 12.3%;p=0.002)。

适用人群与场景

  • 2015年1月至2023年1月法国16个ICU收治的成人念珠菌血症患者,至少一次血培养念珠菌属阳性。

研究设计与关键结果

  • CandidICU为回顾性多中心队列研究,在16个法国ICU开展,纳入2015年1月至2023年1月收治的492例成人念珠菌血症患者。
  • 492例中376例(76.4%)接受了继发性定位病灶筛查,82例(21.8%)诊断出至少一个继发性定位病灶。
  • 竞争风险分析显示SAPSII评分(sdHR 1.01,95%CI 1.00-1.02;p=0.031)和血培养阳性持续时间(sdHR 1.05,95%CI 1.02-1.08;p=0.003)为继发性定位病灶的独立危险因素。
  • 年龄(sdHR 0.98,95%CI 0.97-1.00;p=0.016)和光滑念珠菌感染(sdHR 0.38,95%CI 0.15-0.99;p=0.048)为继发性定位病灶的保护因素。
  • 继发性定位病灶患者抗真菌治疗时间更长(18[11-30]天 vs 14[6-18]天;p<0.001),抗真菌药物升级比例更高(27.8% vs 12.3%;p=0.002)。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU念珠菌血症患者中,SAPSII评分较高和血培养阳性持续时间较长者继发性定位病灶风险更高,年龄较轻和光滑念珠菌感染者风险较低(作者结论)。
  • 继发性定位病灶的筛查和发生与抗真菌治疗时间延长及抗真菌药物升级比例升高相关(作者结论)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Candidemia is a life-threatening fungal infection in intensive care unit (ICU) patients that can be complicated by secondary localization (SL). However, the prevalence, risk-factors, and outcomes of patients with secondary localization during candidemia remain poorly explored.

METHODS: The CandidICU study was a retrospective multicenter cohort study conducted in 16 French ICUs. All adult patients hospitalized from 01-2015 to 01-2023 for candidemia were enrolled. We assessed the prevalence and risk-factors for SL. In addition, we explored the clinical course according to the screening and occurrence of SL.

RESULTS: Among 492 patients hospitalized in ICU with at least one positive blood culture for Candida sp., 376 were screened for SL (76.4%). At least one SL was diagnosed in 82 patients (21.8%). Competing risk analysis identified the SAPSII score and the duration of positive blood cultures as independent risk factors for SL (sdHR 1.01 [95%CI 1.00-1.02]; p = 0.031 and sdHR 1.05 [95%CI 1.02-1.08]; p = 0.003, respectively). Age and Candida glabrata infection were protective factors against SL (sdHR 0.98 [95%CI 0.97-1.00]; p = 0.016 and sdHR 0.38 [95%CI 0.15-0.99]; p = 0.048, respectively). Finally, patients with SL received longer antifungal treatment (18 [11-30] versus 14 [6-18] days; p < 0.001) and had a higher rate of antifungal escalation (27.8% versus 12.3%; p = 0.002).

CONCLUSIONS: In this cohort, 76·4% of ICU patients with candidemia were screened for SL and at least one SL was diagnosed in 21·8%. The severity at ICU admission and duration of positive blood cultures were identified as independent risk factors for SL, whereas age and Candida glabrata infection were protective. Finally, the screening and occurrence of SL were associated with significant changes in the management of patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reizine F, Henry J, Desmedt L, et al. Screening, prevalence, and risk factors for secondary localization during candidemia in intensive care unit patients: the French CandidICU multicenter study. Crit Care. 2025. PMID: 40618139. doi:10.1186/s13054-025-05527-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。